NCT04238416View on ClinicalTrials.gov

Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions
Hepatic EncephalopathyAcute-On-Chronic Liver Failure
Interventions
DRUG

Branched chain amino acid

Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm

DRUG

Lactulose

Oral lactulose will be given to patients in both arms

Trial Locations (1)

160012

PGIMER, Chandigarh

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT04238416 - Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF | Biotech Hunter | Biotech Hunter